0000000000548047

AUTHOR

Jose D. González-sanmiguel

showing 2 related works from this author

Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols

2020

PETHEMA, HOVON, PALG, GATLA cooperative groups.

MaleMultivariate analysisOverweightTOXICITYBody Mass Index0302 clinical medicineLeukemia Promyelocytic AcuteRecurrenceAcute promyelocytic leukemiaAntineoplastic Combined Chemotherapy ProtocolsDIFFERENTIATION SYNDROMEOutcomeAged 80 and overAIDA protocolMercaptopurineMortality rateIncidence (epidemiology)HematologyGeneral MedicineMiddle AgedPrognosisTreatment OutcomeVincristinePopulation Surveillance030220 oncology & carcinogenesisFemalemedicine.symptomUnderweightAdultmedicine.medical_specialtyAdolescentACUTE MYELOID-LEUKEMIADIAGNOSISYoung Adult03 medical and health sciencesInternal medicinemedicineAsparaginaseHumansObesityRisk factorAgedRESPONSE CRITERIAOVERWEIGHTbusiness.industrynutritional and metabolic diseasesANTHRACYCLINEmedicine.diseaseObesityRISK-ADAPTED TREATMENTMethotrexateTRANS-RETINOIC ACIDPrednisonebusinessBody mass index030215 immunologyEuropean Journal of Haematology
researchProduct

Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet

2015

In 2008, a European registry of relapsed acute promyelocytic leukemia was established by the European LeukemiaNet. Outcome data were available for 155 patients treated with arsenic trioxide in first relapse. In hematological relapse (n=104), 91% of the patients entered complete hematological remission (CR), 7% had induction death and 2% resistance, 27% developed differentiation syndrome and 39% leukocytosis, whereas no death or side effects occurred in patients treated in molecular relapse (n=40). The rate of molecular (m)CR was 74% in hematological and 62% in molecular relapse (P=0.3). All patients with extramedullary relapse (n=11) entered clinical and mCR. After 3.2 years median follow-u…

MaleCancer ResearchInternational CooperationGastroenterologyArsenicalsEuropean LeukemiaNetchemistry.chemical_compoundArsenic TrioxideLeukemia Promyelocytic AcuteRecurrence80 and overCumulative incidenceProspective StudiesRegistriesLeukocytosisArsenic trioxideChildAged 80 and overPromyelocyticLeukemiaCell DifferentiationOxidesHematologyMiddle AgedEuropeLeukemiaTreatment OutcomeOncologyChild PreschoolFemalemedicine.symptomAdultAcute promyelocytic leukemiamedicine.medical_specialtyAdolescentAntineoplastic AgentsAcuteDisease-Free SurvivalYoung AdultInternal medicinemedicineHumansAutologous transplantationPreschoolAgedbusiness.industrymedicine.diseaseSurgeryTransplantationAdolescent; Adult; Aged; Aged 80 and over; Antineoplastic Agents; Arsenicals; Cell Differentiation; Child; Child Preschool; Disease-Free Survival; Europe; Female; Humans; International Cooperation; Leukemia Promyelocytic Acute; Male; Middle Aged; Oxides; Prospective Studies; Recurrence; Registries; Treatment Outcome; Young AdultchemistrybusinessSettore MED/15 - Malattie del SangueLeukemia
researchProduct